Copyright Reports & Markets. All rights reserved.

Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Squamous Non-Small Cell Lung Cancer Therapeutics Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Product
      • 1.4.2 BMS-906024
      • 1.4.3 Buparlisib Hydrochloride
      • 1.4.4 FP-1039
      • 1.4.5 Ipilimumab
      • 1.4.6 JNJ-42756493
      • 1.4.7 Lenvatinib
      • 1.4.8 Others
    • 1.5 Market by End User
      • 1.5.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by End User
      • 1.5.2 Research Center
      • 1.5.3 Hospital
      • 1.5.4 Clinic
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size
      • 2.1.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue 2014-2025
      • 2.1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales 2014-2025
    • 2.2 Squamous Non-Small Cell Lung Cancer Therapeutics Growth Rate by Regions
      • 2.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Regions
      • 2.2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Manufacturers
      • 3.1.1 Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Manufacturers
      • 3.1.2 Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Manufacturers
      • 3.1.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.2 Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Manufacturers
      • 3.2.1 Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Manufacturers (2014-2019)
      • 3.2.2 Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Share by Manufacturers (2014-2019)
    • 3.3 Squamous Non-Small Cell Lung Cancer Therapeutics Price by Manufacturers
    • 3.4 Squamous Non-Small Cell Lung Cancer Therapeutics Manufacturing Base Distribution, Product Types
      • 3.4.1 Squamous Non-Small Cell Lung Cancer Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Squamous Non-Small Cell Lung Cancer Therapeutics Product Type
      • 3.4.3 Date of International Manufacturers Enter into Squamous Non-Small Cell Lung Cancer Therapeutics Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Product
    • 4.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Product
    • 4.3 Squamous Non-Small Cell Lung Cancer Therapeutics Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by End User

    6 North America

    • 6.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics by Countries
      • 6.1.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Countries
      • 6.1.2 North America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Squamous Non-Small Cell Lung Cancer Therapeutics by Product
    • 6.3 North America Squamous Non-Small Cell Lung Cancer Therapeutics by End User

    7 Europe

    • 7.1 Europe Squamous Non-Small Cell Lung Cancer Therapeutics by Countries
      • 7.1.1 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Countries
      • 7.1.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics by Product
    • 7.3 Europe Squamous Non-Small Cell Lung Cancer Therapeutics by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics by Countries
      • 8.1.1 Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Countries
      • 8.1.2 Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics by Product
    • 8.3 Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics by End User

    9 Central & South America

    • 9.1 Central & South America Squamous Non-Small Cell Lung Cancer Therapeutics by Countries
      • 9.1.1 Central & South America Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Countries
      • 9.1.2 Central & South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Squamous Non-Small Cell Lung Cancer Therapeutics by Product
    • 9.3 Central & South America Squamous Non-Small Cell Lung Cancer Therapeutics by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics by Countries
      • 10.1.1 Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Countries
      • 10.1.2 Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics by Product
    • 10.3 Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics by End User

    11 Company Profiles

    • 11.1 Ascenta Therapeutics, Inc.
      • 11.1.1 Ascenta Therapeutics, Inc. Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products Offered
      • 11.1.5 Ascenta Therapeutics, Inc. Recent Development
    • 11.2 AstraZeneca Plc
      • 11.2.1 AstraZeneca Plc Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Products Offered
      • 11.2.5 AstraZeneca Plc Recent Development
    • 11.3 AVEO Pharmaceuticals, Inc.
      • 11.3.1 AVEO Pharmaceuticals, Inc. Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products Offered
      • 11.3.5 AVEO Pharmaceuticals, Inc. Recent Development
    • 11.4 Bayer AG
      • 11.4.1 Bayer AG Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Products Offered
      • 11.4.5 Bayer AG Recent Development
    • 11.5 BIND Therapeutics, Inc.
      • 11.5.1 BIND Therapeutics, Inc. Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products Offered
      • 11.5.5 BIND Therapeutics, Inc. Recent Development
    • 11.6 Boehringer Ingelheim GmbH
      • 11.6.1 Boehringer Ingelheim GmbH Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Products Offered
      • 11.6.5 Boehringer Ingelheim GmbH Recent Development
    • 11.7 Bristol-Myers Squibb Company
      • 11.7.1 Bristol-Myers Squibb Company Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Products Offered
      • 11.7.5 Bristol-Myers Squibb Company Recent Development
    • 11.8 Eli Lilly and Company
      • 11.8.1 Eli Lilly and Company Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Products Offered
      • 11.8.5 Eli Lilly and Company Recent Development
    • 11.9 F. Hoffmann-La Roche Ltd.
      • 11.9.1 F. Hoffmann-La Roche Ltd. Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Products Offered
      • 11.9.5 F. Hoffmann-La Roche Ltd. Recent Development
    • 11.10 Five Prime Therapeutics, Inc.
      • 11.10.1 Five Prime Therapeutics, Inc. Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Products Offered
      • 11.10.5 Five Prime Therapeutics, Inc. Recent Development
    • 11.11 Genentech, Inc.
    • 11.12 Incyte Corporation
    • 11.13 Johnson & Johnson
    • 11.14 MacroGenics, Inc.
    • 11.15 Novartis AG
    • 11.16 Oncogenex Pharmaceuticals, Inc.
    • 11.17 PsiOxus Therapeutics Limited

    12 Future Forecast

    • 12.1 Squamous Non-Small Cell Lung Cancer Therapeutics Market Forecast by Regions
      • 12.1.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Forecast by Regions 2019-2025
    • 12.2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Forecast by Product
      • 12.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Forecast by Product 2019-2025
      • 12.2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Forecast by Product 2019-2025
    • 12.3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Forecast by End User
    • 12.4 North America Squamous Non-Small Cell Lung Cancer Therapeutics Forecast
    • 12.5 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Forecast
    • 12.6 Asia Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Forecast
    • 12.7 Central & South America Squamous Non-Small Cell Lung Cancer Therapeutics Forecast
    • 12.8 Middle East and Africa Squamous Non-Small Cell Lung Cancer Therapeutics Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Squamous Non-Small Cell Lung Cancer Therapeutics Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Squamous Non-Small Cell Lung Cancer Therapeutics market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Squamous Non-Small Cell Lung Cancer Therapeutics market based on company, product type, end user and key regions.

      This report studies the global market size of Squamous Non-Small Cell Lung Cancer Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Squamous Non-Small Cell Lung Cancer Therapeutics in these regions.
      This research report categorizes the global Squamous Non-Small Cell Lung Cancer Therapeutics market by top players/brands, region, type and end user. This report also studies the global Squamous Non-Small Cell Lung Cancer Therapeutics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Ascenta Therapeutics, Inc.
      AstraZeneca Plc
      AVEO Pharmaceuticals, Inc.
      Bayer AG
      BIND Therapeutics, Inc.
      Boehringer Ingelheim GmbH
      Bristol-Myers Squibb Company
      Eli Lilly and Company
      F. Hoffmann-La Roche Ltd.
      Five Prime Therapeutics, Inc.
      Genentech, Inc.
      Incyte Corporation
      Johnson & Johnson
      MacroGenics, Inc.
      Novartis AG
      Oncogenex Pharmaceuticals, Inc.
      PsiOxus Therapeutics Limited

      Market size by Product
      BMS-906024
      Buparlisib Hydrochloride
      FP-1039
      Ipilimumab
      JNJ-42756493
      Lenvatinib
      Others
      Market size by End User
      Research Center
      Hospital
      Clinic

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Squamous Non-Small Cell Lung Cancer Therapeutics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Squamous Non-Small Cell Lung Cancer Therapeutics market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Squamous Non-Small Cell Lung Cancer Therapeutics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Squamous Non-Small Cell Lung Cancer Therapeutics submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Squamous Non-Small Cell Lung Cancer Therapeutics are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Squamous Non-Small Cell Lung Cancer Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now